Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Candex is a brand name used for antifungal medications, most commonly containing nystatin or clotrimazole, depending on the regional market. In its nystatin formulation (e.g., as marketed by Adcock Ingram), it is a polyene antifungal derived from *Streptomyces noursei*. It is indicated for the treatment of localized *Candida* infections, such as oral thrush, cutaneous candidiasis, and intestinal infections. The drug works by binding to ergosterol in the fungal cell membrane, creating transmembrane pores that lead to the leakage of essential intracellular components and subsequent cell death. Because nystatin is not significantly absorbed through the skin or mucous membranes, Candex is primarily used for local effect. It is important to note that 'Candex' is also the name of a popular enzyme-based dietary supplement used for yeast management, which is a distinct non-pharmaceutical product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Candex.